Medytoxin
Phase 3Biologic
Medytoxin is one of 22 biologic programs targeting Cervical Dystonia. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Cervical Dystonia
#DrugCompanyPhaseTrials
1Botox
AbbVieApproved
BOTULINUM TOXIN TYPE B
EisaiApproved
Dysport
IpsenApproved
Xeomin
MMerz Therapeutics GmbH
Approved
NT 201
MMerz Pharmaceuticals GmbH
Approved
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 3
Ingrezza
Neurocrine BiosciencesPhase 2
Marinol
Alnylam PharmaceuticalsPhase 2
Meditoxin
MMedy-Tox
Phase 3
Fycompa
CCatalyst Biosciences
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Medytoxin. EMBL-EBI & Wellcome Sanger Institute.
- [4]